Lepu Biopharma Co. Ltd. (2157)

Overview

Lepu Biopharma Co., Ltd. is a prominent biopharmaceutical entity committed to the innovation and development of oncology therapeutics in China. Established in 2018 and headquartered in Shanghai, the company leverages advanced scientific methodologies to address critical needs in cancer treatment. Its focus spans a broad spectrum of cancer types, with a significant emphasis on conducting rigorous clinical trials to ensure efficacy and safety. By harnessing cutting-edge biotechnological approaches, Lepu Biopharma endeavors to make substantive contributions to the field of oncology, improving patient outcomes and quality of life.

Products and Services

• HX008

A cutting-edge humanized IgG4 monoclonal antibody (mAb) targeting PD-1. It is designed for the treatment of solid tumors and melanoma. HX008 has reached phase III clinical study in combination with irinotecan, and it is undergoing phase II clinical trials addressing non-small cell lung cancer, triple-negative breast cancer, and hepatocellular carcinoma.

• MRG003

This investigational drug targets nasopharyngeal cancer and head and neck squamous cell carcinoma. Currently, MRG003 is in the midst of a phase II clinical study, demonstrating the company's commitment to expanding its portfolio in addressing diverse and challenging cancer types.

• MRG002

MRG002 is under phase II clinical trials for the treatment of gastric cancer, gastroesophageal junction cancer, and urothelial cancer. The focus on these specific cancer types indicates Lepu Biopharma's dedication to tackling both common and less prevalent cancers with potential for significant patient impact.

• MRG001 CD20-targeted ADC

A promising antibody-drug conjugate (ADC) that targets CD20, MRG001 is currently in phase II trials. It represents the company's efforts in utilizing ADC technology to target cancers more precisely, potentially reducing side effects associated with traditional cancer treatments.

• CMG9013 CLDN18.2-targeted ADC

CMG9013 is another ADC under development, targeting CLDN18.2 in patients. This approach is in phase II trials, highlighting Lepu Biopharma's investment in ADC technology to cater to specific cancer molecular signatures for more effective treatments.

• MRG004A TF-targeted ADC

Reflecting the latest addition to Lepu Biopharma's ADC pipeline, MRG004A is a tissue factor (TF)-targeted ADC currently undergoing phase I trials. This phase represents the initial steps of clinical development, aiming to assess the safety, tolerability, and preliminary efficacy of the drug.